Secukinumab
MAXIMISE: Secukinumab significantly improves signs, symptoms of axial disease in PsA
Secukinumab in doses of 300 and 150 mg significantly improves signs and symptoms of axial disease, compared with placebo, in patients with psoriatic arthritis with axial manifestations, according to data.
Secukinumab not superior to adalimumab in patients with SpA who failed prior biologics
Although secukinumab performs similarly to adalimumab in patients with spondyloarthritis who failed their first biological treatment, adalimumab proved superior in those who failed multiple biologics, according to data.
Secukinumab provides 'significant, sustained' fatigue reduction in ankylosing spondylitis
Secukinumab demonstrated rapid, stained improvements in fatigue for up to 3 years among patients with ankylosing spondylitis, according to data published in Arthritis Care & Research.
Latent TB infection uncommon after secukinumab treatment
AxSpa treatment expands beyond 'workhorse' TNF inhibitors
Strong data for two interleukin-17 inhibitors have given a lift to clinicians treating the spondyloarthropathies, according to a presenter at the 2020 Congress of Clinical Rheumatology-West.
IL-17 inhibitors offer promising 'effective' treatment for ankylosing spondylitis
IL-17 inhibitors have recently demonstrated “quite effective” results in treating ankylosing spondylitis, according to a speaker at the 2020 Congress of Clinical Rheumatology-East.
Risankizumab may be superior to secukinumab in psoriasis treatment
Risankizumab demonstrated superiority to secukinumab in patients with moderate to severe plaque psoriasis, according to study results presented at the American Academy of Dermatology virtual meeting.
IL-17 inhibitors effective for ankylosing spondylitis, but boost infection risk
Treatment with IL-17 inhibitors significantly increases response rates among patients with ankylosing spondylitis, but with an increased risk for non-severe infections, according to a meta-analysis published in Arthritis Research & Therapy.
Secukinumab safe, effective for Behçet's phenotype resistant to conventional treatment
Secukinumab was safe and effective for Behçet’s syndrome among patients with a mucosal and articular phenotype refractory to previous conventional and biologic treatments, according to data published in the Annals of the Rheumatic Diseases.
FDA expands approval of secukinumab for nonradiographic axial spondyloarthritis
The FDA has expanded the approval of secukinumab to include treatment of active nonradiographic axial spondyloarthritis, allowing this drug to treat patients across the entire axSpA spectrum.